Device Trial Radar · NCT00295802
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer
Last checked: Nov 21, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
141
Actual
Start
Apr 2006
Primary completion
Aug 2012
Study completion Sep 2014
Sponsor
- Lead sponsor
- EDAP TMS S.A.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the substantial equivalence of the Ablatherm high intensity focused ultrasound (HIFU) as compared to cryotherapy for the treatment of low risk, localized prostate cancer.
Conditions
- Prostate Cancer
Interventions
Integrated Imaging High Intensity Focused UltrasoundDevice
Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)Device
Cryotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsyTime frame: Through 24 month period
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Chinn & Chinn Urology Associates
Arcadia, California
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.